Carlos Oliveira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Carlos Oliveira has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Vaclav Vetvicka
Department of Pathology University of Louisville USA
5 shared publications Alcindo A. Dos Santos
Department of Fundamental Chemistry/Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil
1 shared publication- Fabio Sabbadin Zanuzzo
Department of Ocean Sciences, Memorial University, St. John’s, Canada
1 shared publication - J.C. Borosky
Borosky & Lesch Ltda, Brasil
1 shared publication - M.C.R. Costa
Kemin Industries, Brasil
1 shared publication Marcos Felipe Pinatto-Botelho
Department of Fundamental Chemistry/Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
- Vol. 75 (6) , 1065-1068
Euglena gracilis as an adjuvant for the treatment of a dog with chronic kidney disease - case report
A young dog diagnosed with chronic kidney disease, based on clinical changes and sonographic findings (IRIS, 2023), was supplemented with 15mg per kg of body weight per day of inactive dried Euglena gracilis (henceforth called IDEG) as an adjuvant to standard treatments used for the management of chronic kidney disease in dogs. The treatments were divided into two stages, with a total duration of 120 days. At the end of the treatments, the patient showed improvement in vitality, interaction, weight gain, reduction in azotemia, and a 44% decrease in serum C-reactive protein levels.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
- Vol. 75 (6) , 1065-1068
Open AccessEuglena gracilis as an adjuvant for the treatment of a dog with chronic kidney disease - case report
A young dog diagnosed with chronic kidney disease, based on clinical changes and sonographic findings (IRIS, 2023), was supplemented with 15mg per kg of body weight per day of inactive dried Euglena gracilis (henceforth called IDEG) as an adjuvant to standard treatments used for the management of chronic kidney disease in dogs. The treatments were divided into two stages, with a total duration of 120 days. At the end of the treatments, the patient showed improvement in vitality, interaction, weight gain, reduction in azotemia, and a 44% decrease in serum C-reactive protein levels.
- 1 February 2019
- Published by Elsevier in Comparative Immunology, Microbiology and Infectious Diseases
- Vol. 62, 1-6
β-Glucan successfully stimulated the immune system in different jawed vertebrate species
- 1 February 2019
- Published by Elsevier in Comparative Immunology, Microbiology and Infectious Diseases
- Vol. 62, 1-6
β-Glucan successfully stimulated the immune system in different jawed vertebrate species
- 1 December 2014
- Vol. 34 (12) , 6939-6944
Evaluation of a Special Combination of Glucan with Organic Selenium Derivative in Different Murine Tumor Models
Beta-glucans are well-established immunomodulators with strong effects resulting in slowing or even inhibiting cancer growth. Recent studies have repeatedly suggested that the biological activities of beta-glucan can be potentiated by the addition of other bioactive agents. In the current study, we focused on the anticancer effects of a combination of yeast-derived beta-glucan and a selenium-linked pseudodisaccharide. Using three different models of murine cancer, we showed that this combination strongly suppressed the growth of all three types of cancers, most likely via the interaction with natural anticancer antibodies.
- 1 December 2014
- Vol. 34 (12) , 6939-6944
Evaluation of a Special Combination of Glucan with Organic Selenium Derivative in Different Murine Tumor Models
Beta-glucans are well-established immunomodulators with strong effects resulting in slowing or even inhibiting cancer growth. Recent studies have repeatedly suggested that the biological activities of beta-glucan can be potentiated by the addition of other bioactive agents. In the current study, we focused on the anticancer effects of a combination of yeast-derived beta-glucan and a selenium-linked pseudodisaccharide. Using three different models of murine cancer, we showed that this combination strongly suppressed the growth of all three types of cancers, most likely via the interaction with natural anticancer antibodies.
- Open Access
- 1 February 2014
- Vol. 2 (2) , 6-16
β(1-3)(1-6)-D-glucans modulate immune status in pigs: potential importance for efficiency of commercial farming
β(1-3)(1-6)-D-glucans modulate immune status in pigs: potential importance for efficiency of commercial farming
- 1 February 2014
- Vol. 2 (2) , 6-16
Open Accessβ(1-3)(1-6)-D-glucans modulate immune status in pigs: potential importance for efficiency of commercial farming
β(1-3)(1-6)-D-glucans modulate immune status in pigs: potential importance for efficiency of commercial farming
- Open Access
- 10 January 2014
- Published by Sciencedomain International in British Journal of Pharmaceutical Research
- Vol. 4 (8) , 981-991
β(1-3)(1-6)-D-glucans Modulate Immune Status and Blood Glucose Levels in Dogs
Aims: The objective of this study is to evaluate the effects of adding two different glucans coded as BGO1 and BGO2 into commercial feed of dogs. Study Design: We measured changes in phagocytosis, levels of IL-2 in blood, antibody formation and level of blood sugar (normal homeostasis and experimentally-induced hyperglycaemie with streptozotocin). Place and Duration of Study: Department of Pathology, University of Louisville, and Department of Research and Development, Biorigin, June 2012 and May 2013. Methodology: The technique employing phagocytosis of synthetic polymeric microspheres was used for evaluation of phagocytic activity. IL-2 production was evaluated in serum by an ELISA kit. Formation of antibodies was tested using ovalbumin as an antigen, level of specific antibodies was measured by ELISA. Blood sugar evaluation was done both in normal animals and in animals with experimentally-induced hyperglycaemie. The level of glucose in serum was measured by Antech Diagnostics. Results: In phagocytosis, both glucans significantly (P ≤0.05 level) increased the phagocytic activity of blood monocytes and neutrophils. Both glucans were active in IL-2 tests, but BG01 activity was 160% of that of BG02. Similar data were achieved in evaluation of effects on antibody response – BG01 reached OD of 0.717, whereas BG02 reached OD 0.411. Blood sugar evaluations showed no effect of glucan on normal dogs, but significant (P ≤0.05 level) reduction in dogs with hyperglycaemie (both glucans showed same activity). Conclusion: Our data showed that both glucans had significant immunomodulating effects in immune reactions in the dog model, strongly suggesting that supplementation of feed with these glucans results in improvement of biological and immunological conditions of dogs.
- 10 January 2014
- Published by Sciencedomain International in British Journal of Pharmaceutical Research
- Vol. 4 (8) , 981-991
Open Accessβ(1-3)(1-6)-D-glucans Modulate Immune Status and Blood Glucose Levels in Dogs
Aims: The objective of this study is to evaluate the effects of adding two different glucans coded as BGO1 and BGO2 into commercial feed of dogs. Study Design: We measured changes in phagocytosis, levels of IL-2 in blood, antibody formation and level of blood sugar (normal homeostasis and experimentally-induced hyperglycaemie with streptozotocin). Place and Duration of Study: Department of Pathology, University of Louisville, and Department of Research and Development, Biorigin, June 2012 and May 2013. Methodology: The technique employing phagocytosis of synthetic polymeric microspheres was used for evaluation of phagocytic activity. IL-2 production was evaluated in serum by an ELISA kit. Formation of antibodies was tested using ovalbumin as an antigen, level of specific antibodies was measured by ELISA. Blood sugar evaluation was done both in normal animals and in animals with experimentally-induced hyperglycaemie. The level of glucose in serum was measured by Antech Diagnostics. Results: In phagocytosis, both glucans significantly (P ≤0.05 level) increased the phagocytic activity of blood monocytes and neutrophils. Both glucans were active in IL-2 tests, but BG01 activity was 160% of that of BG02. Similar data were achieved in evaluation of effects on antibody response – BG01 reached OD of 0.717, whereas BG02 reached OD 0.411. Blood sugar evaluations showed no effect of glucan on normal dogs, but significant (P ≤0.05 level) reduction in dogs with hyperglycaemie (both glucans showed same activity). Conclusion: Our data showed that both glucans had significant immunomodulating effects in immune reactions in the dog model, strongly suggesting that supplementation of feed with these glucans results in improvement of biological and immunological conditions of dogs.